The extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes

Journal of Cardiology

Volumn 61, Issue 1, 2013, Pages 58-64

  Takahama, Hiroyuki ^a   Yokoyama, Hiroyuki ^a   Kada, Akiko ^a   Sekiguchi, Kenichi ^a   Fujino, Masashi ^a   Funada, Akira ^a   Amaki, Makoto ^a   Hasegawa, Takuya ^a   Asakura, Masanori ^a   Kanzaki, Hideaki ^a   Anzai, Toshihisa ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Acute heart failure; Beta blocker; Heart rate

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART BEAT; HEART DISEASE; HEART RATE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROGNOSIS; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; FORECASTING; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PROSPECTIVE STUDIES; RISK; SYNDROME; TREATMENT OUTCOME;

EID: 84872374142     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.08.014     Document Type: Article

References (26)

1. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
2. Lechat P., Hulot J.S., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBISII trial. Circulation 2001, 103:1428-1433.
3. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., Gilbert E.M., Johnson M.R., Goss F.G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: metoprolol in dilated cardiomyopathy (MDC) Trial Study Group. Lancet 1993, 342:1441-1446.
4. Hirano K., Yamashita T., Suzuki S., Hayama E., Matsuoka J., Otsuka T., Sagara K., Fu L.T., Sawada H., Aizawa T., Nakazato Y., Daida H. Relationship between 24-h Holter recordings and clinical outcomes in patients with permanent atrial fibrillation. J Cardiol 2012, 60:42-46.
5. Böhm M., Swedberg K., Komajda M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomizd placebo-controlled trial. Lancet 2010, 376:886-894.
6. Kaye D.M., Lefkovits J., Jennings G.L., Bergin P., Broughton A., Esler M.D. Adverse consequence of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26:1257-1263.
7. Floras J.S. Symathetic nervous system activation in human heart failure. J Am Coll Cardiol 2009, 54:375-385.
8. Colucci W.S., Packer M., Bristow M.R., Gilbert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretsky B.F., Bowers J.A., Sackner-Bernstein J.D., Young S.T., Holcslaw T.L., Lukas M.A. Carvedilol inhibits clinical progression in patients with mild symtoms of heart failure, US Carvedilol Heart Failure Study Group. Circulation 1996, 94:2800-2806.
9. Willenheimer R., van Veldhuisen D.J., Silke B., Erdmann E., Follath F., Krum H., Ponikowski P., Skene A., van de Ven L., Verkenne P., Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005, 112:2426-2435. CIBIS III Investigators.
10. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971, 285:1441-1446.
11. Hata N., Seino Y., Tsutamoto T., Hiramitsu S., Kaneko N., Yoshikawa T., Yokoyama H., Tanaka K., Mizuno K., Nejima J., Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure - the PROTECT multicenter randomized controlled study. Circ J 2008, 72:1787-1793.
12. Gheorghiade M., Abraham W.T., Albert N.M., Greenberg B.H., O'Connor C.M., She L., Stough W.G., Yancy C.W., Young J.B., Fonarow G.C. OPTIMIZE-HF investigators and coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 18:2217-2226.
13. Heagerty P.J., Zeheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005, 61:92-105.
14. Braunwald E. Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol 1971, 27:416-432.
15. Colin P., Ghaleh B., Monnet X., Hittinger L., Berdeaux A. Effects of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004, 308:236-240.
16. Bache R.J., Cobb F.R. Effects of maximal coronary vasodilation on transmural myocardial perfusion during tachycardia in the awake dog. Circ Res 1977, 64:648-653.
17. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., Yamamoto M., Miyaji K., Saito H., Morita H., Emori T., Matsubara H., Toyokuni S., Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 24:2867-2871.
18. Packer M. Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation 1990, 2(Suppl.):I77-I88.
19. Kaye D., Esler M. Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res 2005, 66:256-264.
20. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Cohn J.N. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283.
21. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L. Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
22. Gheorghiade M., Zannad F., Sopko G., Klein L., Piña I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., Tavazzi L. International working group on acute heart failure syndromes. Acute heart failure syndromes; current state and framework for future research. Circulation 2005, 112:3958-3968.
23. Gheorghiade M., Pang P.S. Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality?. J Am Coll Cardiol 2009, 53:2349-2352.
24. Mulieri L.A., Hasenfuss G., Leavitt B., Allen P.D., Alpert N.R. Altered myocardial force-frequency relation in human heart failure. Circulation 1992, 85:1743-1750.
25. Kishi T. Heart failure as an autonomic nervous system dysfunction. J Cardiol 2012, 59:117-122.
26. Hori M., Sasayama S., Kitabatake A., Toyo-oka T., Handa S., Yokoyama M., Matsuzaki M., Takeshita A., Origasa H., Matsui K., Hosoda S. MUCHA Investigators. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J 2004, 147:324-330.